Innovative vaccines for a healthier world
Interview with CEO Bent Frandsen
Next Event
-
Thu16May202410:00H.C. Andersen Capital Webinar
Presentation of 2024 first quarter results
Join ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander as they provides insights into the 2023 fourth quarter and full-year results. Visit the H.C. Andersen Capital Events website for further details and registration information.
Latest News
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS
Hørsholm, Denmark, 23 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announced that it has been notified by the Board of Directors of its associated company, AdaptVac ApS, of the resolution to pay a dividend of DKK 42.5 million (SEK 66.1 million) to its owners. As a result of ExpreS2ion…
Read moreExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the Board of Directors of ExpreS2ion has resolved to postpone the Company's annual general meeting and consequently also the publication of the annual report for 2023 due to administrative and practical reasons.
Read moreExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate
Hørsholm, Denmark, 16 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce the completion of the final report for the Good Laboratory Practice (GLP) safety study in non-human primates of the ES2B-C001 (HER2-VLP) breast cancer vaccine candidate.
Read more